The guanylate cyclase stimulator vericiguat: Insights and adverse events from a FAERS-based pharmacovigilance study
{{output}}
Background: Since its approval by the U.S. Food and Drug Administration in January 2021, vericiguat, a novel soluble guanylate cyclase stimulator, has been increasingly utilized in the treatment of heart failure with reduced ejec... ...
